Article Information
History
- March 21, 2023.
Article Versions
- You are currently viewing Version 1 of this article (March 21, 2023 - 19:36).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Aidan M. Nikiforuk1,4,
- Kevin S. Kuchinski1,2,
- Katy Short3,
- Susan Roman3,
- Mike A. Irvine1,
- Natalie Prystajecky1,2,
- Agatha N. Jassem1,2,
- David M. Patrick1,4 and
- Inna Sekirov1,2,*
- 1British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada
- 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
- 3Fraser Health Authority, New Westminster, BC V3L 3C2, Canada
- 4School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
- 5Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
- ↵* Corresponding author; email: inna.sekirov{at}bccdc.ca
Posted March 21, 2023.
Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Expression as a Risk-Factor for SARS-CoV-2 Transmission in Concurrent Hospital Associated Outbreaks
